Loomis Sayles & Co. L P Has $737,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Loomis Sayles & Co. L P decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 90.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,075 shares of the specialty pharmaceutical company's stock after selling 182,234 shares during the quarter. Loomis Sayles & Co. L P owned about 0.06% of Collegium Pharmaceutical worth $737,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Gladius Capital Management LP purchased a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $32,000. nVerses Capital LLC boosted its position in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,600 shares during the period. GAMMA Investing LLC increased its position in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 792 shares during the period. CWM LLC increased its stake in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after buying an additional 736 shares during the period. Finally, AXA S.A. acquired a new position in Collegium Pharmaceutical during the 2nd quarter worth approximately $209,000.

Wall Street Analyst Weigh In

COLL has been the subject of several research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. HC Wainwright boosted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 23rd. Finally, Truist Financial boosted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded down $0.48 during trading on Thursday, reaching $30.71. The company had a trading volume of 682,214 shares, compared to its average volume of 447,095. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm's 50 day simple moving average is $35.28 and its two-hundred day simple moving average is $34.65. The company has a market capitalization of $990.40 million, a PE ratio of 13.24 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a one year low of $25.16 and a one year high of $42.29.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares of the company's stock, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.